Search company, investor...

Biocept

biocept.com

Founded Year

1997

Stage

IPO | IPO

Total Raised

$27.6M

Date of IPO

2/5/2014

Market Cap

0.01B

Stock Price

0.76

Revenue

$0000 

About Biocept

Biocept is a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and biomarker analysis, headquartered in San Diego, California. The company's mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Biocept utilizes patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, the company offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support.

Headquarters Location

9955 Mesa Rim Rd

San Diego, California, 92121,

United States

858-320-8200

Missing: Biocept's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Biocept's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Biocept

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biocept is included in 2 Expert Collections, including Cancer.

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Biocept Patents

Biocept has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/30/2017

8/18/2020

Molecular biology, Genetics, Biotechnology, DNA, Polymerase chain reaction

Grant

Application Date

10/30/2017

Grant Date

8/18/2020

Title

Related Topics

Molecular biology, Genetics, Biotechnology, DNA, Polymerase chain reaction

Status

Grant

Latest Biocept News

In Brief This Week: Biocept, Thermo Fisher, Biodesix, More

Nov 23, 2022

Save for later NEW YORK – Biocept this week reported that its third quarter revenues shrunk more than threefold year over year to $5.6 million from $17.5 million in Q3 2021, primarily due to a drop in revenues from RT-PCR COVID-19 testing. Excluding this testing revenue, Biocept's Q3 revenues fell 10 percent to about $900,000 from $1 million a year ago. The San Diego-based company said that Q3 orders for its CNSide assay for detecting tumor cells in cerebrospinal fluid in patients with suspected CNS metastases increased 176 percent year over year and 8 percent sequentially. Biocept's Q3 net loss swelled to $5.5 million, or $.33 per share, from $625,000, or $.04 per share, a year ago. The company finished the quarter with $18.0 million in cash. Thermo Fisher Scientific this week issued €1.25 billion ($1.29 billion) worth of senior notes in a public offering. According to the company, €500 million of the notes are due in 2026 with an interest rate of 3.20 percent, and €750 million are due in 2034 with an interest rate of 3.65 percent. Thermo Fisher said interest for both notes will be paid annually. Biodesix said this week that it has raised $40.3 million in gross proceeds from its previously announced public offering of 35,075,000 shares of its common stock at $1.15 per share. This includes the exercise in full by the underwriter to purchase up to an additional 4,575,000 shares at $1.15 per share. William Blair was the sole bookrunning manager for the offering. Castle Biosciences said this week that the College of American Pathologists (CAP) has accredited its clinical laboratory facility in Pittsburgh following the necessary on-site inspection. Castle took on the Pittsburgh lab through its acquisition of Cernostics in December 2021. BGI Group said this week that it has signed three memorandums of understanding — with the Indonesian Ministry of Health, the University of Indonesia, and the Del Institute of Technology — in the lead-up to the G20 Summit in Bali. The memorandums of understanding cover genomics development initiatives, the construction of related laboratories, and joint research and personnel training, according to BGI. Malaysian Genomics Resource Center this week reported a 59 percent year-over-year decrease in revenues for its fiscal first quarter 2023. For the quarter ended Sept. 30, the firm recorded RM 3.81 million ($830,000) in revenues, down from RM 9.32 million a year ago. Earnings per share for Q1 were SEN .68 compared to SEN .20 the year before. The Petaling Jaya, Malaysia-based company said it has been refocusing its biopharmaceutical business on immunotherapy and cell therapies and pushing growth of its genetic screening business. It also seeks to acquire assets or invest in firms that will support the expansion of the genetic screening business. The firm said it is equipped with a high-throughput sequencing lab, a microarray facility, and a cGMP cell processing lab for cell therapies, including immunotherapies for various cancer types. In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.

Biocept Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biocept Rank

Biocept Frequently Asked Questions (FAQ)

  • When was Biocept founded?

    Biocept was founded in 1997.

  • Where is Biocept's headquarters?

    Biocept's headquarters is located at 9955 Mesa Rim Rd, San Diego.

  • What is Biocept's latest funding round?

    Biocept's latest funding round is IPO.

  • How much did Biocept raise?

    Biocept raised a total of $27.6M.

  • Who are the investors of Biocept?

    Investors of Biocept include Goodman Co. and Needham Capital Partners.

  • Who are Biocept's competitors?

    Competitors of Biocept include CirculoGene Diagnostics, Freenome, Chronix Biomedical, Accuragen, Genomic Health and 13 more.

Compare Biocept to Competitors

Owlstone Medical Logo
Owlstone Medical

Owlstone Medical is a diagnostics company developing a breathalyzer for disease detection. Its Breath Biopsy platform enables early detection across multiple cancers and a range of other conditions. Breath Biopsy can also be used to enable precision medicine, ensuring that the right drug is given to the right patient at the right time, helping to improve patient outcomes and reduce healthcare costs. The company was founded in 2004 and is based in Cambridge, England.

20/20 GeneSystems Logo
20/20 GeneSystems

20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.

Freenome Logo
Freenome

Freenome is an AI genomics biotechnology company in South San Francisco, California. By using a blood test, Freenome can help detect and treat cancer quickly and efficiently.

OncoTAB Logo
OncoTAB

OncoTAB's technology was used to develop a blood test, Agkura Personal Score, which aids breast cancer detection in women with dense breast tissue.

A
Accuragen

Accuragen has developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in minuscule concentrations of circulating cell-free DNA (cfDNA) in blood. The Company's technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining proprietary techniques in molecular biology and computational algorithm for error suppression. With Accuragen's technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.

L
Liquid Genomics

Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.